Byooviz 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
N/0014 
Minor change in labelling or package leaflet not 
11/01/2024 
PL 
connected with the SPC (Art. 61.3 Notification) 
II/0012/G 
This was an application for a group of variations. 
05/10/2023 
n/a 
B.I.a.4.z - Change to in-process tests or limits 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
applied during the manufacture of the AS - Other 
variation 
B.I.a.2.b - Changes in the manufacturing process of 
the AS - Substantial change to the manufacturing 
process of the AS which may have a significant 
impact on the quality, safety or efficacy of the 
medicinal product 
IA/0013 
B.II.d.2.a - Change in test procedure for the finished 
02/08/2023 
n/a 
product - Minor changes to an approved test 
procedure 
PSUSA/2609/
Periodic Safety Update EU Single assessment - 
12/05/2023 
n/a 
PRAC Recommendation - maintenance 
202210 
ranibizumab 
IB/0010 
B.II.f.1.d - Stability of FP - Change in storage 
21/02/2023 
07/12/2023 
SmPC and PL 
conditions of the finished product or the 
diluted/reconstituted product 
IA/0011 
B.I.b.2.a - Change in test procedure for AS or 
16/01/2023 
n/a 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
IB/0007 
B.II.f.1.b.5 - Stability of FP - Extension of the shelf 
04/01/2023 
07/12/2023 
SmPC 
life of the finished product - Biological/immunological 
medicinal product in accordance with an approved 
stability protocol 
IA/0008 
B.II.f.1.e - Stability of FP - Change to an approved 
16/12/2022 
n/a 
stability protocol 
Page 2/3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0006 
C.I.2.a - Change in the SPC, Labelling or PL of a 
15/12/2022 
07/12/2023 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0005 
C.I.11.z - Introduction of, or change(s) to, the 
10/11/2022 
n/a 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
IB/0004 
B.I.z - Quality change - Active substance - Other 
05/10/2022 
n/a 
variation 
IB/0003 
B.II.f.1.b.5 - Stability of FP - Extension of the shelf 
11/04/2022 
29/09/2022 
SmPC 
life of the finished product - Biological/immunological 
medicinal product in accordance with an approved 
stability protocol 
IAIN/0002 
B.II.e.5.a.1 - Change in pack size of the finished 
12/10/2021 
29/09/2022 
SmPC, 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
Labelling and 
PL 
Page 3/3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
